

# Blanca Xicoy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2535807/publications.pdf>

Version: 2024-02-01

127  
papers

3,033  
citations

218381

26  
h-index

174990

52  
g-index

142  
all docs

142  
docs citations

142  
times ranked

3602  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 3005-3015.	0.6	251
2	Cytogenetic risk stratification in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2011, 96, 375-383.	1.7	226
3	Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. <i>Blood</i> , 2010, 116, 1205-1210.	0.6	202
4	Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2012, 97, 310-317.	1.7	194
5	Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 958-963.	0.6	182
6	Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 172-183.	2.0	135
7	Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 191-198.	1.7	124
8	Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2020, 136, 1851-1862.	0.6	112
9	Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1752-1761.	0.6	98
10	Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. <i>Leukemia</i> , 2015, 29, 1875-1881.	3.3	93
11	Allogeneic transplantation of CD34+selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells?. <i>Blood</i> , 2001, 98, 2352-2357.	0.6	71
12	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. <i>Annals of Hematology</i> , 2014, 93, 2037-2043.	0.8	66
13	Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2006, 78, 061114074547002-???	1.1	63
14	Outcome and Prognostic Factors in Patients with Hematologic Malignancies Admitted to the Intensive Care Unit: A Single-Center Experience. <i>International Journal of Hematology</i> , 2007, 85, 195-202.	0.7	59
15	The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , 2014, 99, e55-e57.	1.7	51
16	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. <i>Leukemia Research</i> , 2015, 39, 296-306.	0.4	50
17	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. <i>Cancer</i> , 2012, 118, 127-133.	2.0	43
18	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2015, 100, 17-22.	1.7	43

#	ARTICLE	IF	CITATIONS
19	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	2.2	39
20	A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2012, 119, 5221-5228.	0.6	37
21	Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies. <i>Annals of the New York Academy of Sciences</i> , 2020, 1466, 93-103.	1.8	35
22	Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 2341-2348.	0.6	34
23	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. <i>Cancer</i> , 2015, 121, 423-431.	2.0	34
24	Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. <i>Aids</i> , 2002, 16, 1973-1976.	1.0	32
25	Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry. <i>Haematologica</i> , 2014, 99, 1395-1402.	1.7	31
26	Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. <i>Annals of Hematology</i> , 2015, 94, 947-954.	0.8	31
27	Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. <i>Oncotarget</i> , 2016, 7, 57021-57035.	0.8	26
28	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2012, 159, 311-321.	1.2	25
29	Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. <i>Lancet Haematology</i> , 2015, 2, e260-e266.	2.2	24
30	Post-transplant Burkitt's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial). <i>Leukemia and Lymphoma</i> , 2003, 44, 1541-1543.	0.6	23
31	Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. <i>European Journal of Haematology</i> , 2014, 93, 487-491.	1.1	23
32	Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 33-38.	1.1	23
33	Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2973-2974.	0.6	21
34	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3284-3292.	0.8	20
35	Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1837-1842.	0.6	19
36	Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. <i>Leukemia Research</i> , 2015, 39, 52-57.	0.4	18

#	ARTICLE	IF	CITATIONS
37	Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. <i>American Journal of Hematology</i> , 2016, 91, 185-192.	2.0	18
38	Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2019, 94, E264-E267.	2.0	17
39	Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. <i>Leukemia and Lymphoma</i> , 2010, 51, 2063-2069.	0.6	16
40	Results of treatment with azacitidine in patients aged $\geq$ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 2014, 55, 1300-1303.	0.6	16
41	Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016, 57, 120-124.	0.6	16
42	Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. <i>Haematologica</i> , 2013, 98, e85-e86.	1.7	15
43	Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. <i>British Journal of Haematology</i> , 2014, 166, 189-201.	1.2	15
44	Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. <i>Leukemia Research</i> , 2015, 39, 1146-1153.	0.4	15
45	The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. <i>Leukemia Research</i> , 2018, 70, 34-36.	0.4	15
46	Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. <i>Oncotarget</i> , 2018, 9, 19342-19355.	0.8	15
47	DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. <i>Epigenetics</i> , 2018, 13, 8-18.	1.3	14
48	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2237-2244.	2.0	14
49	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. <i>Cancer</i> , 2022, 128, 2441-2448.	2.0	14
50	Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. <i>Annals of Hematology</i> , 2012, 91, 1887-1895.	0.8	12
51	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS). <i>American Journal of Hematology</i> , 2017, 92, 614-621.	2.0	12
52	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. <i>Modern Pathology</i> , 2016, 29, 1541-1551.	2.9	11
53	Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E152-E154.	2.0	11
54	Immediate Effects of Dasatinib on the Migration and Redistribution of Na <sup>+</sup> -ve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 1340.	1.6	11

#	ARTICLE	IF	CITATIONS
55	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplantation, 2022, 57, 416-422.	1.3	11
56	AA-type Amyloid Tumor as an Unsuspected Cause of Residual Mass in a Patient With Large B-cell Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2002, 43, 681-682.	0.6	10
57	Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Medicina Clínica, 2013, 141, 95-99.	0.3	10
58	Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy. International Journal of Hematology, 2007, 86, 337-342.	0.7	8
59	Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. Medicina Clínica, 2011, 136, 323-328.	0.3	8
60	Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. Leukemia and Lymphoma, 2012, 53, 1966-1970.	0.6	8
61	Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial. Blood, 2020, 136, 28-29.	0.6	8
62	Effectiveness of Local Radiotherapy in Primary Extranodal Marginal Zone B-cell Lymphoma of MALT or MALT Lymphoma of Conjunctiva: Study of Four Cases. Leukemia and Lymphoma, 2002, 43, 1975-1977.	0.6	7
63	Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. Leukemia and Lymphoma, 2009, 50, 1718-1720.	0.6	7
64	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. British Journal of Haematology, 2021, 194, 708-717.	1.2	7
65	Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older. European Journal of Haematology, 2015, 95, 576-582.	1.1	6
66	Highly variable mutational profile of ASXL1 in myelofibrosis. European Journal of Haematology, 2016, 97, 331-335.	1.1	6
67	Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. American Journal of Hematology, 2017, 92, E534-E541.	2.0	6
68	Response to highly active antiretroviral therapy as the only therapy in an HIV-infected patient with interfollicular Hodgkin's lymphoma. Leukemia and Lymphoma, 2007, 48, 2058-2059.	0.6	5
69	Pharmacogenetic analysis in the treatment of Hodgkin lymphoma. Leukemia and Lymphoma, 2013, 54, 1706-1712.	0.6	5
70	Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review. Cytometry Part B - Clinical Cytometry, 2021, 100, 292-295.	0.7	5
71	Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. Cancers, 2021, 13, 841.	1.7	5
72	Intensive Chemotherapy (High-Dose CHOP/ESHAP Regimen) Followed by Autologous Stem-Cell Transplantation (ASCT) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL). Results of a Prospective Phase II Study from the GELCAB.. Blood, 2005, 106, 2077-2077.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. <i>Leukemia Research</i> , 2014, 38, 304-309.	0.4	4
74	Polycythemia Vera Evolution to Chronic Myelomocytic Leukemia: The Prognostic Value of Next Generation Sequencing. <i>HemaSphere</i> , 2020, 4, e466.	1.2	4
75	Distinct mutational pattern of myelodysplastic syndromes with and without 5qâ€“ treated with lenalidomide. <i>British Journal of Haematology</i> , 2020, 189, e133-e137.	1.2	4
76	Pro-B acute lymphoblastic leukemia in a patient with severe congenital neutropenia: an unusual form of malignant evolution. <i>Leukemia and Lymphoma</i> , 2013, 54, 2325-2327.	0.6	3
77	Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators. <i>Blood</i> , 2012, 120, 3593-3593.	0.6	3
78	Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. Spanish MDS Group (GESMD). <i>Blood</i> , 2012, 120, 3803-3803.	0.6	3
79	Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. <i>Hla</i> , 2022, 99, 93-104.	0.4	3
80	Association of <i>JAK2</i> Mutation Status and Cytogenetic Abnormalities at Diagnosis in Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2012, 137, 677-678.	0.4	2
81	Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome. <i>Leukemia Research</i> , 2018, 73, 24-28.	0.4	2
82	Is There a Role for Autologous Stem-Cell Transplantation (ASCT) in Peripheral T-Cell Lymphoma (PTCL)? Final Results of a Prospective Phase II Study from the GELCAB.. <i>Blood</i> , 2006, 108, 3070-3070.	0.6	2
83	Prognostic Impact of Monosomal Karyotype in Patients with Myelodysplastic Syndrome and Abnormal Karyotype. A Report From the Spanish Group of MDS (GESMD). <i>Blood</i> , 2011, 118, 1724-1724.	0.6	2
84	Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. <i>Leukemia and Lymphoma</i> , 0, , 425-430.	0.6	2
85	Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients. <i>HemaSphere</i> , 2021, 5, e657.	1.2	2
86	Systemic thrombotic thrombocytopenic purpura (TTP) following unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1173-1175.	0.6	1
87	Chronic myelomonocytic leukemia diagnosed by means of mutational analysis in a patient with persistent monocytosis and tuberculosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 2297-2298.	0.6	1
88	Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 2015, 94, 869-871.	0.8	1
89	Impact of previous admission to an intensive care unit on stem cell transplantation outcome. <i>Medicina Clínica</i> , 2020, 155, 382-387.	0.3	1
90	Effectiveness of Various Dosage Regimens of Azacitidine In Patients with Myelodysplastic Syndromes: Safety and Efficacy Final Data From the Spanish Azacitidine Compassionate Use Registry. <i>Blood</i> , 2010, 116, 1853-1853.	0.6	1



#	ARTICLE	IF	CITATIONS
91	Safety and Efficacy of Dasatinib Treatment Change for Patients Previously Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study. <i>Blood</i> , 2016, 128, 5450-5450.	0.6	1
92	Analysis of Transfusion Dependency Development and Disease Evolution in Patients with MDS with 5q- and without Transfusion Needs at Diagnosis. <i>Blood</i> , 2016, 128, 3180-3180.	0.6	1
93	Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis. <i>Leukemia Research</i> , 2022, 112, 106771.	0.4	1
94	International Sentinel Site Surveillance of Patients with Transfusional Hemosiderosis Treated with Deferasirox in Actual Practice Setting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S85.	0.2	0
95	Utilidad del lavado broncoalveolar y la citometría de flujo en pacientes con hemopatías malignas e insuficiencia respiratoria. <i>Medicina Clínica</i> , 2017, 148, 297-302.	0.3	0
96	Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients. <i>Biopreservation and Biobanking</i> , 2017, 15, 360-365.	0.5	0
97	Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos. <i>Medicina Clínica</i> , 2018, 150, 421-427.	0.3	0
98	Tratamiento actual de las neoplasias mieloproliferativas: frente a tres escenarios. <i>Medicina Clínica</i> , 2020, 154, 131-133.	0.3	0
99	Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification. <i>Leukemia Research</i> , 2021, 111, 106726.	0.4	0
100	Outcome and Prognostic Factors in Patients with Hematological Malignancy That Are Admitted to the Intensive Care Unit. <i>Blood</i> , 2004, 104, 5285-5285.	0.6	0
101	Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients. <i>Blood</i> , 2005, 106, 774-774.	0.6	0
102	Comparison of Immunohistochemical (IHC) Expression Profile and Prognosis in 98 Patients with Diffuse Large B Cell Non-Hodgkin's Lymphoma (DLBCL) with and without Human Immunodeficiency Virus (HIV) Infection. <i>Blood</i> , 2007, 110, 4403-4403.	0.6	0
103	Azacitidine In Compassionate Use: Response to Therapy, Survival, and Prognostic Factors In 200 Patients Diagnosed with MDS or AML. <i>Blood</i> , 2010, 116, 2933-2933.	0.6	0
104	Clinical and Biological Characteristics According to the Burden of JAK2V617F Mutated Allele in BCR-ABL Negative MPNs. <i>Blood</i> , 2012, 120, 1437-1437.	0.6	0
105	Characterization of Cytogenetic Abnormalities and Mutations in ASXL1, SRSF2, CBL and JAK2 Genes in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2012, 120, 4809-4809.	0.6	0
106	Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis. <i>Blood</i> , 2013, 122, 1542-1542.	0.6	0
107	Aplicability Of The Predictive Model Of Response To Erythropoetic Stimulating Agents (ESA) From Myelodysplastic Syndromes (MDS) and Analysis Of Response and Overall Survival (OS) In a Series Of 99 Patients (Pts) With Chronic Myelomonocytic Leukemia (CMML) From The Spanish Registry Of MDS and The Düsseldorf-MDS Registry, Germany. <i>Blood</i> , 2013, 122, 2813-2813.	0.6	0
108	Whole-Exome Sequencing In Myelodysplastic Syndromes With 5q- and Normal Karyotype. <i>Blood</i> , 2013, 122, 1551-1551.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predictive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial. Blood, 2013, 122, 5190-5190.	0.6	0
110	Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score. Blood, 2013, 122, 2754-2754.	0.6	0
111	Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. Blood, 2014, 124, 4659-4659.	0.6	0
112	Advanced Stage Hodgkin's Lymphoma Has More Aggressive Characteristics but Similar Outcome in HIV-Infected Than in HIV-Negative Patients in the Combination Antiretroviral Therapy Era. Blood, 2014, 124, 4435-4435.	0.6	0
113	Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referral Center 2007-2013. Blood, 2014, 124, 4647-4647.	0.6	0
114	Comparison of Three Prognostic Scoring Systems in a Series of 146 Cases of Chronic Myelomonocytic Leukemia (CMML): MD Anderson Prognostic Score (MDAPS), CMML-Specific Prognostic Scoring System (CPSS) and Mayo Prognostic Model. Blood, 2014, 124, 4660-4660.	0.6	0
115	Frequency and Prognosis of JAK2 V617F, Calr, MPL and ASXL1 Mutations in Primary Myelofibrosis. Blood, 2014, 124, 5562-5562.	0.6	0
116	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML) and Adverse Karyotype. Subanalysis from the Alma Study. Blood, 2014, 124, 945-945.	0.6	0
117	Mutational Studies Using Next Generation Sequencing in High Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients Treated with Azacitidine (High risk MDS 2009 protocol) Tj ETQq1 1 0.784314 rgBT /Over	0.6	0
118	Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features. Blood, 2015, 126, 2883-2883.	0.6	0
119	Methylation Patterns in Patients with High-Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Treated with Azacitidine (high-risk MDS 2009 protocol from CETLAM Group). Blood, 2015, 126, 1682-1682.	0.6	0
120	Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression. Blood, 2015, 126, 4015-4015.	0.6	0
121	Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category. Blood, 2016, 128, 3185-3185.	0.6	0
122	Application of Trusight Myeloid Panel on Whole Genome Amplified DNA in Myelodysplastic Syndrome Patients. Blood, 2016, 128, 5519-5519.	0.6	0
123	Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q). Blood, 2016, 128, 3172-3172.	0.6	0
124	Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study. Blood, 2016, 128, 4834-4834.	0.6	0
125	Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts. Blood, 2016, 128, 1991-1991.	0.6	0
126	Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the "Sintra-REV" Clinical Trial. Blood, 2020, 136, 26-27.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of <i>ASXL1</i> Chromosomal Deletion and Genetic Mutations. <i>Blood</i> , 2020, 136, 1-2.	0.6	0